Abstract:Background: Threats by enforced Intellectual Property (IP) rights to equitable HIV treatment access by poor populations are impending. India and China's policy directions in the field will be crucial in ultimately affecting the affordability and accessibility of antiretroviral (ARV) therapy in the under-served markets. These directions, together with the exploitation level of IP-bound flexibilities and the evolutionary modelling in partnerships and trade agreements between research-based and generic pharmaceutical industry, will also affect the outcomes of self-sufficiency efforts now at their beginning in the developing world as far as domestic manufacturing of generic ARV drugs is concerned. Aims: This paper explores key issues, implications and interaction dynamics across these challenging scenarios while attempting to provide equitable solution glimpses into the near future. Results: Access-oriented long-term drug policy strategies entitled to pass muster of governments, research-based as well as generic industries in both developed and developing countries are needed if equitable access to affordable ARV treatments by poor people has to be achieved despite enforced IP rights. Predictable dynamics between western multinationals and transitional country generic corporations let regard IP-bound Voluntary License flexibilities as a fitting measure into just mentioned needs especially if substantial incentives to generic corporations are concurrently secured. Efforts to equitably expand ARV drug access through exploiting IP opportunities should encompass attainment of self-sufficiency in domestic drug manufacturing whenever basic requirements are in place in the developing world as a whole. A credible industrial potential would act, indeed, as a boosting factor for drawing branded drug producers into technology transfer agreements, the terms of which would let all contractors enjoy substantial advantages. These perspectives consistently bind up with the foreseeable long-term trade and drug policy directions of India and China according to frontier crossing implications of their key IP management trends as well as their multifaceted penetration strategies of both the wealthy and under-served markets worldwide. As coherent with these perspectives, more disbursement by wealthy country governments and donors to basic infrastructure development in sub-Saharan African nations with stable governments in place is urged both as a priority for improving Africa's economy and a prerequisite for allowing domestic industrial plants to take off. Aiming at the targets just underscored, WHO's brokering role in negotiated agreements between wealthy and developing country-based firms as well as its technical guidance in setting international standards have always to be sought if equitable and appropriate end results are to be attained. Conclusion: Overall insights in this paper would mean that, while research-based corporations are to be praised whenever waiving, on humanitarian purposes, part of their profits, the trade and profit rules cannot basically be given up if long-term sustainable results are the goal to look for. Only negotiated agreements securing all contracting parties lasting advantages may ensure shifting of such a goal from mere vision to a really sustainable attainment.

TRIPS and the Primacy of Public Health

TRIPS Agreement and Public Health

TRIPS to Where? A Narrative Review of the Empirical Literature on Intellectual Property Licensing Models to Promote Global Diffusion of Essential Medicines

Temporary Waiver of Patent Rights in Public Health Emergencies: Inadequacy of Provisions during the COVID-19 Crisis

The right to health and medicines: the case of recent multilateral negotiations on public health, innovation and intellectual property

Patents, trade and medicines: past, present and future

Intellectual Property, COVID-19 Vaccines and Equity: A Public Health and Human Rights Critique

Intellectual Property as a Determinant of Health

Drug Patent Monopoly During Covid-19 Outbreaks: How the Government Regulates this?

The Trans-Pacific Partnership and pharmaceutical innovation

Evaluating the Usefulness of Compulsory Licensing in Developing Countries: A Comparative Study of Thai and Brazilian Experiences Regarding Access to Aids Treatments

Product patents and access to innovative medicines

Reconciling the global public health interest with intellectual property protection through the waiver of certain provisions of the WTO TRIPS Agreement

The Role of Intellectual Property Rights and Access to Medical Products in the WHO African Region: 25 Years After the Trips Agreement

Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?

The role of intellectual property rights on access to medicines in the WHO African region: 25 years after the TRIPS agreement

Global Health Jurisprudence: COVID-19 Pandemic and Pharmaceutical Patents

The COVID-19 Pandemic and the TRIPS Waiver: Patents and Flexibility

Balance of Interests and Humanitarian Concerns

Protection of intellectual property and human rights during health emergencies: an assessment of the patent waiver proposal

Challenges faced by the Indian Pharmaceutical Companies in protecting various forms of Intellectual Property Rights